Abiopharma

🔍 Keilaf Omer David (Director)

Company: Innoviz Technologies Ltd. (INVZ)

Report Date: 2026-04-30

Detailed Transactions and Holdings:

• Sold 723,019 shares of Ordinary Shares (Direct)
  Date: 2026-04-30 | Code: J | equity_swap_involved: 0 | shares_owned_after: 3,505,931.00 | transaction_form_type: 4 | Footnotes: F1

Footnotes:

• F1: Represents a transfer of 723,019 ordinary shares from the Reporting Person to his former spouse, Ms. Gali Moscovici, pursuant to a divorce settlement.
• F2: The amount includes 1,135,780 ordinary shares issuable upon vesting of restricted share units ("RSUs"); of which (a) 15,596 RSUs granted August 9, 2022, vesting in equal quarterly installments through 2026; (b) 36,630 RSUs granted August 1, 2023, vesting quarterly through 2027; (c) 74,008 RSUs granted February 27, 2024, with 14,232 vesting quarterly through 2027 and 59,776 vesting quarterly through 2028; (d) 60,590 RSUs granted August 20, 2024, vesting quarterly through 2028; (e) 82,092 RSUs granted February 25, 2025, vesting quarterly through 2029; (f) 750,000 RSUs granted May 26, 2025, one-fourth vesting on May 26, 2026, remainder vesting quarterly through 2029; and (g) 116,864 RSUs granted August 5, 2025, one-fourth vesting on August 5, 2026, remainder vesting quarterly through 2029. Vesting is subject to the Reporting Person remaining a service provider of the Issuer on each applicable vesting date. Each RSU represents a contingent right to receive one ordinary share.
• F3: No exercise price is applicable.